Clinical Trial

Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with schizophrenia. In addition, several drugs with antioxidant properties have been tested in clinical trials for the treatment of schizophrenia too. Whether combined treatment of an NMDA-enhancing agent and a drug with antioxidant property can be better than an NMDA-enhancing agent alone deserves study.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2021-06-30; most recent amendment 2025-02-16.
Trial Details
NCT Number NCT04959201
Lead Sponsor China Medical University Hospital
Collaborators: Ministry of Science and Technology, Taiwan
Conditions Schizophrenia
Enrollment 90 participants
Start Date 2020-11-30
Primary Completion 2026-12 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2025-02-19